Shared Perspectives on Strategies, Markets and Innovation from Safeguard Scientifics

Archive: Exits


Point-of-Care Testing gains ground with BD’s acquisition of Alverix

In 2007, Alverix set out to revolutionize point-of-care (POC) testing–medical tests conducted in the doctor’s office, at a patient’s bedside, in a clinic or even in a patient’s home. POC testing offers convenience and swift results. But to be effective, the tests must be absolutely accurate. Alverix’s products, which leverage optoelectronics, offer portability and affordability yet they can also detect…

Read more


Internet of Things gets boost with PTC acquisition of ThingWorx

In February 2011—long before the term “Internet of Things” became a hot business buzzword—Safeguard Scientifics saw potential in ThingWorx, the first application platform that lets designers build and run Internet of Things (IoT) and Machine-to-Machine (M2M) applications. Since 2011, Safeguard has deployed $10 million in ThingWorx, which was founded in 2009 and based in Exton, Pa. Safeguard’s ability to spot…

Read more

A Look Ahead

The State of Safeguard: Where We’ve Been and Where We’re Going

During my nearly five years at Safeguard, I’ve worked closely with my predecessor, Peter Boni, and the current management team to define our strategy and develop plans to achieve our objective to build value for our shareholders. Over the past several months since the board asked me to become President and CEO, I have spent considerable time talking with the…

Read more

Life Sciences

Anatomy of a Deal: Avid Radiopharmaceuticals

This morning, I presented at the 2012 Annual RBC Biotech Conference, which focused on the “Biotech Success Stories of the [Philadelphia] Region”. I was asked to speak about Safeguard’s success with our life sciences partner company, Avid Radiopharmaceuticals, which was acquired in December 2012 by Eli Lilly. The following presentation, entitled “The Success of Avid Pharmaceuticals from an Investor’s Point…

Read more

Investor Relations

RECAP: Safeguard Scientifics Second Quarter 2012 Financial Results

This morning, we announced Safeguard Scientifics’ second quarter 2012 results and reported on developments at Safeguard and our partner companies, which included customer wins, strategic partnerships, changes and additions in senior management, and regulatory advancements. As a result of continued momentum at Safeguard’s partner companies, Safeguard increased 2012 aggregate partner company revenue guidance to a range of $170 million to…

Read more